Results Of the 739 HCV patients investigated, 84 (11%) had resolved infections without receiving treatment. These 84 individuals were less likely to be male (42% vs. 62%, p-value=0.0007), black (19% vs. 47%,

p-value<0.0001), and were younger (median: 31 years vs. 49 years, p-value <0.0001) than those with chronic infections. Chronically infected individuals were more likely to be in care for HCV (61% vs. 35%, p <0.005) and have histories of IDU (54% vs. 23%, p-value <0.0001) or incarceration (54% vs. 16%, p-value <0.0001). Discussion Our findings support prior studies showing that African-Americans and males are less likely to show spontaneous clearance of HCV. The association between high risk behavior and reduced HCV clearance may be partially explained by reinfection with new viral strains, see more though further studies are warranted. By defining the mechanisms underlying viral control, it may be possible to utilize robust surveillance data to target individuals for treatment and/ or care using risk and

demographic indicators. The use of new medications for HCV treatment with this enhanced targeting technique may allow for additional clearance of HCV infection in non-resolved patients. Disclosures: The Idasanutlin nmr following people have nothing to disclose: Danica Kuncio, Amy Hueber, Claire Newbern, Kendra Viner Purpose: Psychiatric side effects, such as depression, are the main reason for discontinuation of interferon-based therapy. Recent developments in near-infrared spectroscopy (NIRS) have enabled the noninvasive clarification of brain functions in psychiatric disorders with measurement of oxy-hemoglobin (oxy-Hb) concentrations

as cerebral blood volume. Methods: We prospectively evaluated the onset of depression in 20 patients with chronic hepatitis C (CHC) by using NIRS. Of those, 10 patients received pegylated interferon alpha combined with ribavirin therapy. The relative concentrations of oxy-Hb during the word fluency task were measured with frontal and temporal probes at the start of treatment and at 4 and 12 weeks, using NIRS. Simultaneously, a questionnaire survey was administrated, using center for epidemiologic studies depression scale (CES-D). Prodromal phase of depression was defined as a CES-D value from 8 to 15, depressive Methocarbamol symptoms as a CES-D>16. Results: Clinical profiles were as follows: male-to-female ratio was 13:7, and mean age was 57.8 ± 8.9 years. The proportions of HCV genotype 1 and 2 were 70% and 30%, respectively. HCV-RNA levels, 6.5 ± 0.7 log IU/ ml, platelet count, 14.4 ± 3.2 x104/mm3, ALT, 58.4 ± 44.1 U/L. The negativity rate of HCV-RNA 12 weeks after the initiation of therapy was 80%. Pegylated interferon alpha mean dose was 136 ± 47 μg/week, and ribavirin mean dose was 760 ± 84 mg/day. Minor depressive symptoms were found in 1 of the 10 patients with interferon-based therapy.